Biocodex is an independent multinational pharmaceutical company built on high-standards science and manufacturing, with six decades of proven success.
Founded in 1953, the company’s initial focus was gastroenterology featuring a unique probiotic Saccharomyces boulardii; the first probiotic drug of its kind that has a positive effect on the gut’s microflora.
Today, Biocodex has transformed itself beyond its probiotic drug roots, expanding its portfolio into a multitude of therapeutic areas which include:
The Turkish Biocodex affiliate was founded in 2009, and is focusing on it’s core probioteic yeast product, Reflor, and Otipax, an ear-drop solution for the treatment of otitis, launched in 2014.
Contact Details
Fatih Sultan Mehmet Mah.
Poligon Cad (Buyaka İş Kuleleri)
Buyaka 2 Sitesi Kule 3 D:15-16-17-18
Meydan AVM – İKEA Yanı
Ümraniye – İstanbul / TÜRKİYE
T: +90 216 640 4141
F: +90 216 640 4130
Biocodex’s new general manager gives an overview of the affiliates ‘new deal’ program, and how the company has adjusted its approach to better fit the contemporary Turkish environment. What attracted…
After an international career spanning 25 years, Demet Russ returned to her native Turkey to lead the Janssen affiliate during a tumultuous time and is aiming to give back to…
Avinash Potnis of Novartis Turkey discusses potential solutions to the country’s access and pricing dilemma which has raised concerns of system sustainability. Potnis also highlights the strengths of Turkey’s healthcare…
Ingrid Drechsel, head of Bayer’s pharma operations in Turkey and Iran, discusses the complexity of managing two countries under economic pressure and the advantages of Bayer’s longstanding relationship in both…
Menarini’s general manager for Turkey, the Middle East and Africa Uğur Bingöl discusses the Italian company’s restructuring in the region and its desire to replicate its success in Turkey across…
The secretary general for Turkey’s Pharmaceutical Manufacturers Association (IEIS), Savaş Malkoç, highlights their objective of increasing R&D expenditure and Turkey’s big opportunity ahead in biosimilars production. In addition, Malkoç discusses…
Janssen’s Managing Director for Turkey, Demet Russ, discusses her return to the country after 25 years abroad, having worked for Johnson & Johnson in different local, regional and global roles…
As one of the leading pharma companies in Turkey, DEVA is pioneering a new approach to generics in the country. Chairman of the Board and CEO Philipp Haas discusses the…
As COVID-19 began spreading through the world, the race to understand the disease by scientists and doctors took off. After just a few months, it became apparent that people with…
The president of the Turkish Society of Cardiology, Mustafa Kemal Erol, discusses the prevalence of cardiovascular disease, which accounts for over a third of deaths in Turkey, the improvements made…
AmCham Turkey’s executive director, Asli Özelli, examines the impact of US companies on the Turkish economy with over USD 50 billion in investment, their help during the pandemic, the chamber’s…
Dr Burak Cem, Novo Nordisk Vice President and General Manager for Turkey, outlines the company’s big bet on Turkey as a future regional hub through deep investment in clinical trials,…
Turkey’s former Minister of Health, Bülent Akarcali, outlines the country’s healthcare system evolution over the past decades, comparing the improvements to the difference between a Ford Model T to a…
See our Cookie Privacy Policy Here
